Opus Genetics (IRD) news
Recent news
Opus Genetics - May offer and sell up to $300 mln of securities - SEC filing
Opus Genetics, Inc. (Nasdaq: IRD) has filed with the U.S. Securities and Exchange Commission (SEC) to offer and sell up to $300 million of securities, according to a recent SEC filing. The company has previously raised capital through registered direct offerings and public offerings, with the most…
AInvest Wire · Aug 7, 2026Opus Genetics - topline six-month efficacy data expected by end of 2027
AInvest Wire · Aug 3, 2026Opus Genetics - May submit BLA based on six-month efficacy data
Opus Genetics, Inc. (Nasdaq: IRD) has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its Phase 3 clinical trial for OPGx-LCA5, a gene therapy targeting LCA5-associated inherited retinal disease. The company announced that it may submit a Biologics License…
AInvest Wire · Aug 3, 2026Opus Genetics - to announce OPGX-Best1 three-month top-line data from cohort 1 in September 2026
Opus Genetics, Inc. (Nasdaq: IRD) has announced that it expects to release three-month top-line data from Cohort 1 of its Phase 1/2 clinical trial of OPGx-BEST1 gene therapy in September 2026. The trial, which evaluates the safety and efficacy of OPGx-BEST1 in patients with Best Vitelliform Macular…
AInvest Wire · Jul 9, 2026Opus Genetics - to initiate Phase 3 dosing in Q4 2026
AInvest Wire · Jul 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.